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Abstract
Aims: The aim of the present study was to compare the rate 
of actionable arrhythmic events between patients with hy-
pertrophic cardiomyopathy (HCM) who are monitored with 
an insertable cardiac monitor (ICM) or Holter monitoring. 
Methods: We studied 50 patients (mean age 52 years, 72% 
men) with HCM at low or intermediate risk for sudden car-
diac death (SCD), of whom 25 patients received an ICM be-
tween November 2014 and February 2019. We retrospec-
tively identified a control group of 25 patients who were 
matched on age, sex, and HCM Risk-SCD score category. The 
mean HCM Risk-SCD score was 3.41 ± 1.31 and 3.31 ± 1.43 
for the ICM and Holter groups, respectively. The primary 
endpoint was an actionable event which was defined as an 
arrhythmic event resulting in a change in patient manage-
ment. The secondary endpoint was the occurrence of ven-
tricular tachycardia (VT). Results: The cumulative action-
able event rate at 30 months was higher in the ICM group 
(51 vs. 27%, log-rank p value <0.01). De novo atrial fibrilla-
tion requiring oral anticoagulation occurred only in the ICM 
group (n = 3). Overall, 4 implantable cardioverter-defibrilla-
tors were implanted for primary prevention (n = 2 in each 
group). The cumulative rate of VT episodes at 30 months 
was similar between groups (23% [ICM group] vs. 42% 
[Holter group], log-rank p value = 0.71). Furthermore, the 
characteristics of VT were similar between groups with re-
gard to the number of beats and rate. Conclusions: In adults 
with HCM, an ICM will detect more arrhythmic events re-
quiring an intervention than a conventional Holter strategy. 
In contrast, the diagnostic yield of detecting VT seems sim-
ilar for both groups. © 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Insertable cardiac monitors (ICMs) provide continu-
ous rhythm monitoring and are useful for the detection 
of infrequent arrhythmias, especially in patients with re-
current unexplained syncope [1]. The exact role of ICMs 
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in patients with hypertrophic cardiomyopathy (HCM) is 
less clear. The current ESC guidelines recommend that 
HCM patients with recurrent episodes of unexplained 
syncope, who are at low risk of sudden cardiac death 
(SCD), should be considered for an ICM [1, 2]. Further-
more, an ICM may be considered for HCM patients with 
frequent unexplained palpitations [2]. However, these 
recommendations are based on scarce data and there are 
no comparative data with ambulatory Holter monitor-
ing [3–5]. The 2014 ESC HCM guidelines recommend 
the use of ambulatory Holter monitoring to detect atrial 
and ventricular arrhythmias every 12–24 months or 
more often in the case of symptoms or left atrial dilata-
tion [2]. Theoretically, the diagnostic yield for the detec-
tion of arrhythmias is higher for an ICM in comparison 
to intermittent Holter monitoring. This higher diagnos-
tic yield may be clinically relevant in this patient popula-
tion. For example, the detection of ventricular tachycar-
dia (VT) may have an impact on risk stratification for 
SCD and the decision to implant an implantable cardio-
verter-defibrillator (ICD) [2, 6, 7]. Furthermore, HCM 
patients with documented atrial fibrillation (AF) should 
receive oral anticoagulation to prevent stroke [2]. In the 
past 5 years, we adopted a strategy to use an ICM in 
HCM patients at low to intermediate risk of SCD for the 
detection of subclinical arrhythmias, with a particular 
emphasis on the detection of VT. The aim of the present 
study was to evaluate the incremental value of ICMs 
compared to a conventional strategy (i.e., Holter moni-




This was a prospective observational study which included all 
consecutive adults with HCM who received a Reveal LINQ 
(Medtronic Inc., Minneapolis, MN, USA) between November 
2014 and February 2019. All patients had an HCM Risk-SCD score 
<6%. The reason for an ICM was a combination of symptoms (e.g., 
recurrent [near] syncope, palpitations), presence of myocardial fi-
brosis (determined by the presence of late gadolinium enhance-
ment [LGE] on cardiac MRI [CMR]) and/or an intermediate risk 
for SCD (5-year risk of SCD ≥ 4 to <6%). The decision to implant 
an ICM was made during a Heart Team consisting of a cardiac 
electrophysiologist and a cardiologist specialized in HCM.
The control group was retrospectively identified from our pro-
spective HCM registry and consisted of a matched cohort who re-
ceived conventional follow-up (intermittent Holter monitoring 
every 6–24 months based on treating physician’s discretion). 
Matching was based on age (with a margin of 5 years), sex, and 
HCM Risk-SCD score category (<4% or ≥4 to <6%). Patients in the 
control group required a minimum of 1 Holter study during fol-
low-up and at least a clinical follow-up of 1 year. This study was 
approved by the Ethics Committee of the Erasmus MC.
ICM Settings
All ICMs were implanted subcutaneously as recommended by 
the manufacturer using the incision and insertion tool. Further-
more, all patients received a handheld activator to indicate their 
symptoms when necessary. The ICM was routinely programmed 
with the following settings: tachycardia detection was set to 176 
bpm for 16 beats; bradycardia setting to 30 bpm for 8 beats; pause 
setting to 4.5 s; and AF setting to “AF only.” Based on the implant-
ing physician’s preferences, other settings could be programmed. 
All devices were connected to the Medtronic CareLink network for 
remote monitoring.
Clinical Follow-Up of ICM Group
ICM patients were discharged on the day of implantation. Ten 
days after implantation, the patients were seen at the outpatient 
clinic to check the implantation site and to interrogate the ICM. 
Afterwards, the patients were seen regularly at the outpatient clin-
ic according to routine patient care. ICM checkups were per-
formed at the outpatient clinic every 6 months or earlier when 
necessary based on symptoms or transmitted episodes. Remote 
monitoring was performed on a daily basis during weekdays. All 
patient-activated episodes and automatically detected episodes 
were classified. In case of an inappropriate automatically detected 
episode, the cause of inappropriate detection was specified, if pos-
sible. Multiple actionable events could occur in 1 patient.
Study Endpoints
The primary endpoint of the study was the occurrence of an 
actionable event which was defined as an arrhythmic event result-
ing in any change in patient management (e.g., start or increase of 
medication, implantation of pacemaker or ICD, and catheter abla-
tion). The secondary endpoint was the occurrence of any VT (at 
least 3 beats), irrespective if this resulted in an actionable event or 
not. A regular wide complex tachycardia was considered a VT if 
there was a sudden onset and a change in the QRS morphology in 
comparison to the baseline rhythm. An irregular wide complex 
tachycardia was considered a VT if there was a sudden onset and 
a polymorphic QRS morphology. A regular wide or narrow com-
plex tachycardia was considered a supraventricular tachycardia 
(SVT) if there was a sudden onset and no change in QRS morphol-
ogy. In case of doubt, a second electrophysiologist was consulted 
for the final diagnosis. For both endpoints, the cumulative event 
rate was determined at 30 months considering the estimated bat-
tery lifetime of the ICM.
Statistical Analysis
Continuous data are presented as mean ± SD or as median with 
interquartile range (IQR) (25th and 75th percentiles), as appropri-
ate. Categorical variables are presented by frequencies and per-
centages. Differences of continuous variables between groups were 
analyzed with unpaired Student’s t test or the Kruskal-Wallis test, 
as appropriate. Differences between categorical variables were 
evaluated using the χ2 test. Cumulative event rates were estimated 
with the Kaplan-Meier method, and differences were compared by 
log-rank test. Statistical analyses were performed using SPSS ver-
sion 25 (IBM Corp., Somers, NY, USA).





A total of 25 HCM patients received an ICM between 
2014 and 2019. We identified 25 matched controls with 
HCM who were seen at the outpatient clinic in the same 
study period. Baseline characteristics of the study popula-
tion are presented in Table 1. The ICM group more often 
had a history of syncope (32% vs. 4%, p = 0.01). Other 
baseline characteristics, including a history of nonsus-
tained VT (NSVT), were similar between groups.
ICM-Detected Arrhythmias and Holter Follow-Up
During a mean follow-up of 17 ± 10 months with the 
ICM, a total of 1,015 episodes were transmitted to the 
CareLink network system. There were 270 (27%) patient-
activated episodes and 745 (73%) automatically detected 
episodes. The majority of patient-activated episodes 
(93%) comprised sinus rhythm with or without ectopy. In 
the control group, 48 Holter recordings were performed 
during follow-up. The median number of Holter record-
ings per patient was 2 (IQR, 1–3). The median interval 
between Holter recordings was 12 (IQR, 5–23) months.
Primary Endpoint
The cumulative event rate for an actionable event was 
higher in the ICM group (51 vs. 27% at 30 months, log-
rank p value <0.01) (Fig. 1). In the ICM group, the follow-
ing actionable events occurred: antiarrhythmic drug ther-
apy (or change in dose) for documented arrhythmias 
(n = 6, 24%), start of non-vitamin K antagonist oral anti-
coagulation for documented AF (n = 3, 12%), electro-
physiology study for symptomatic SVT (n = 2, 8%), im-
plantation of ICD for primary prevention (n = 2, 8%), 
pacemaker implantation for sinus node dysfunction (n = 
1, 4%), and external electrical cardioversion for AF (n = 
1, 4%). In the control group, the following actionable 
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Age, years 51±16 52±16 0.94
Sex, male 18 (72%) 18 (72%) 1.00
NYHA functional class ≥II 7 (28%) 7 (28%) 1.00
History of myectomy 2 (8%) 3 (12%) 0.64
Left ventricular systolic function
Normal (EF ≥50%) 25 (100%) 24 (96%) 1.00
Mildly impaired (EF 45–49%) 0 1 (4%)
Genetic testing 21 (84%) 23 (92%) 0.67
Pathogenic mutation 12 (48%) 14 (56%) 0.57
MYBPC3 8 (32%) 11 (44%) 0.38
MYH7 3 (12%) 1 (4%) 0.30
TPM1 1 (4%) 0 1.00
TNNI3 0 2 (8%) 0.49
History of NSVT 13 (52%) 8 (32%) 0.15
History of unexplained syncope 8 (32%) 1 (4%) 0.01
Peak LVOT gradient 6 (5–17) 12 (6–82) 0.19
Family history of SCD 3 (12%) 3 (12%) 1.00
Left atrial size 43±9 45±7 0.23
Maximum left ventricular wall 
thickness 18±5 18±5 0.49
HCM Risk-SCD score 3.41±1.31 3.31±1.43 0.79
<4% 13 (52%) 13 (52%) 1.00
≥4 to ≤6% 12 (48%) 12 (48%) 1.00
Electrocardiography 25 (100%) 25 (100%) 1.00
Sinus rhythm 24 (96%) 25 (100%) 1.00
AF 1 (4%) 0 1.00
PR interval, if sinus rhythm 164±25 182±25 0.85
QRS duration, ms 105±18 102±28 0.56
QTc duration, ms 426±25 416±28 0.61
Holter monitoring 25 (100%) 25 (100%) 1.00
<1% PVCs 23 (92%) 25 (100%) 0.49
1–10% PVCs 2 (8%) 0 0.49
NSVT 11 (44%) 6 (24%) 0.14
SVT 7 (28%) 12 (48%) 0.15
AF 2 (8%) 0 0.49
Cardiac medication 16 (64%) 19 (76%) 0.35
Beta blocker 12 (48%) 14 (56%) 0.57
Loop diuretics 5 (20%) 0 0.05
ACE-inhibitor/ARB 6 (24%) 3 (12%) 0.27
Oral anticoagulants 5 (20%) 5 (20%) 1.00
Calcium channel blocker 3 (16%) 4 (16%) 0.68
Amiodarone/sotalol 2 (8%) 2 (8%) 1.00
Data are presented as n (%), mean ± SD, or median with IQR. ACE, an-
giotensin converting enzyme; ARB, angiotensin receptor blocker; CAD, cor-
onary artery disease; EF, ejection fraction; HCM, hypertrophic cardiomy-
opathy; LVOT, left ventricular outflow tract; NSVT, nonsustained ventricu-
lar tachycardia; NYHA, New York Heart Association; PVC, premature 
ventricular complex; SCD, sudden cardiac death; IQR, interquartile range; 
SVT, supraventricular tachycardia; AF, atrial fibrillation.


















in dose) for documented arrhythmias (n = 6, 24%), im-
plantation of ICD for primary prevention (n = 2, 8%), and 
electrophysiology study for symptomatic SVT (n = 1, 
4%). De novo AF only occurred in the ICM group. Of the 
3 patients with de novo AF, only 1 patient who experi-
enced symptoms required an electrical cardioversion for 
persistent AF.
Overall, 4 patients received an ICD for primary pre-
vention (2 in each group). A patient in the ICM group 
had an ICM-detected NSVT (7 beats, 171 bpm, patient-
activated) which increased his HCM Risk-SCD score 
from 3.6% to 8.0%. He received a prophylactic ICD 15 
months after his ICM implantation. The other patient 
in the ICM group had a history of NSVT, HCM Risk-
SCD score of 4.44%, and patchy LGE anterior wall and 
interventricular septum on his CMR. He experienced an 
episode of fast monomorphic NSVT (32 beats, 200 bpm, 
automatically detected) 12 months post-ICM implanta-
tion. This did not increase his HCM Risk-SCD score, 
but based on his clinical profile and the malignant char-
acter of the VT, the patient received an ICD. In the con-
trol group, a patient received a prophylactic ICD after a 
Holter-detected monomorphic VT episode (3 beats, 
135 bpm) increased his HCM Risk-SCD score from 
4.4% to 9.6% at 27 months after initial risk evaluation. 
The second patient in the control group who received a 
prophylactic ICD had an HCM Risk-SCD score of 4.2% 
and had a history of NSVT. The combination of Holter-
detected recurrent VT and recurrent near syncope was 
the indication for an ICD 26 months after initial risk 
evaluation.
Secondary Endpoint
The cumulative event rate for VT was 23% in the ICM 
group and 42% in the control group at 30 months (log-
rank p value = 0.71) (Fig. 2). Most VT episodes (4 of 5, 
80%) in the ICM group were patient-activated episodes, 
and thus, were detected while patients experienced symp-
toms. One patient of the ICM group had a VT episode 
which was automatically detected (32 beats, 200 bpm). 
The characteristics of documented VT episodes were 
similar between groups with regard to the median num-
ber of documented beats (5 [IQR, 5–7] vs. 6 [IQR, 4–11], 
for the ICM group and the control group, respectively, 
p = 1.00) and median rate (150 bpm [IQR, 145–155 bpm] 
vs. 136 bpm [IQR, 125–168 bpm], for the ICM group and 
the control group, respectively, p = 0.21).
Discussion
The present study is the first study comparing the val-
ue of an ICM to conventional Holter monitoring in HCM 
patients with a low or intermediate HCM Risk-SCD 
score. The main finding is that actionable arrhythmic 
events occurred more frequently in the ICM group in 
comparison to the Holter group. In contrast, the cumula-
tive rate of detected VT was similar between both groups.
It is well-known that prolonged arrhythmia monitor-
ing increases the yield of arrhythmia detection. The indi-
cations for an ICM has expanded over the years, and its 
use is currently not only limited to patients with recurrent 
unexplained syncope [1, 8]. Other important indications 
include the detection of subclinical AF, risk stratification 
in patients with inheritable heart disease by the detection 
of VT, and establishing a symptom-rhythm correlation in 
symptomatic patients [9]. In patients with HCM who are 
at low risk for SCD according to the HCM Risk-SCD 
score, the current ESC guidelines recommends that an 
ICM should be considered in patients with recurrent un-
explained syncope and may be considered in those with 
unexplained palpitations [1, 2]. However, limited data ex-
ist on the clinical impact of ICMs in HCM patients, and 
most studies comprised <10 patients [3–5].
The present study is the first to provide insight into the 
incremental value of an ICM in patients with HCM. The 
rate of actionable arrhythmic events was higher in the 
ICM group in comparison to a matched group who had 
intermittent Holter monitoring. Interestingly, de novo 
AF requiring oral anticoagulation only occurred in the 
ICM group. It is known that AF occurs in approximately 
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paired quality of life, thromboembolism, and mortality 
[10–15]. To prevent thromboembolic complications, the 
guidelines recommend the use of lifelong oral anticoagu-
lation, irrespective of the CHADS-VASc score, when AF 
occurs in patients with HCM [2]. Several studies in HCM 
patients with a cardiac implantable electronic device have 
demonstrated a high incidence of clinically silent AF epi-
sodes which may have important implications [13, 16]. In 
our study, 3 patients (12%) were started on oral antico-
agulation after the detection of de novo AF detected by 
the ICM. Thus, an ICM may play a role in the detection 
of subclinical AF in this specific population.
SCD is the most feared consequence of HCM, which 
has led to meticulous efforts to identify those patients 
who may benefit from a prophylactic ICD. Since 2014, the 
HCM Risk-SCD model provides guidance to physicians 
to identify patients deemed to be at high risk for SCD, and 
thus eligible for a prophylactic ICD [17, 18]. In clinical 
practice, however, we are confronted with patients with a 
low or intermediate risk who have additional risk factors 
which are not incorporated in the HCM Risk-SCD mod-
el, such as extensive LGE on CMR [19], LV apical aneu-
rysms, multiple pathogenic sarcomere protein variants, 
and LV dysfunction. The presence of NSVT is an impor-
tant risk factor, especially in those patients younger than 
30 years of age [20, 21]. In the American guidelines, there 
is class IIa indication for an ICD in patients with NSVT 
who have additional SCD modifiers (i.e., age <30 years, 
LGE on CMR, LVOT obstruction, LV aneurysm, and 
syncope >5 years ago) [6]. Considering the clinical rele-
vance of documenting VT in this population, routine am-
bulatory Holter monitoring is recommended [2, 6, 7].
We expected that continuous monitoring with an ICM 
would improve VT detection. Interestingly, in our study, 
the diagnostic yield for detecting VT was similar between 
the ICM and Holter groups. This apparent paradox can be 
partly explained by the ICM settings. Only longer and fast-
er runs of VT (≥16 beats at a rate of >176 bpm) or symp-
tomatic VT (patient-activated episodes) will be detected by 
the ICM, while with Holter monitoring, a VT of ≥3 beats 
at a rate of >120 bpm will suffice. The Reveal LINQ can be 
programmed to detect a tachycardia of 5 beats at a rate of 
>120 bpm. However, this sensitive programming setting 
will result in a suboptimal signal-to-noise ratio, as many 
tachycardia episodes will be due to sinus tachycardia.
There is some inconsistency in literature with regard to 
the prognostic significance of specific characteristics of 
documented VT. Studies in unselected HCM cohorts have 
shown no association between characteristics of the detect-
ed VT on ambulatory Holter monitoring and the occur-
rence of SCD [21]. However, several HCM cohorts with 
ICDs (higher-risk cohorts) demonstrated that longer-last-
ing and faster VTs were more predictive of the occurrence 
of appropriate ICD therapy [22–24]. For example, in 160 
HCM patients with ICDs, Wang et al. [24] reported the 
independent association of fast (>200 bpm), long (>7 
beats), and repetitive runs of VT with the occurrence of 
ICD therapy, whereas this association was not shown for 
slower, shorter, and single run of VT [24]. These data are 
important and support the use of ICMs as these devices are 
able to capture the more predictive longer and faster VT.
Finally, there are some factors that need to be consid-
ered when using ICMs in this patient population, includ-
ing device costs, data overload, the clinical relevance of 
detected arrhythmias, and medical overuse. A dedicated 
telemonitoring staff is a requirement before providing 
such a service to patients.
Study Limitations
Although we used a matched control group, the present 
study is a nonrandomized study and selection bias is pos-
sible. The control group had a lower proportion of patients 
with a history of syncope. It is important to stress that the 
ICM population was not a general HCM population, but a 
selected cohort of HCM patients with symptoms or addi-
tional risk factors for SCD. Finally, the classification of wide 
complex tachycardia as either VT or SVT can be challeng-
ing considering that only a single surface electrogram is 
available. To reduce the risk of misclassification, difficult 
electrograms were reevaluated by an electrophysiologist.
Conclusions
In patients with HCM, the use of an ICM resulted in 
more actionable arrhythmic events if compared to inter-
mittent Holter monitoring. Interestingly, de novo AF was 
only detected in the ICM group. The diagnostic yield of 
detecting VT appeared similar between both rhythm de-
tection strategies, which may be explained by the ICM not 
detecting short runs of VT.
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